Next Article in Journal
Pharmacokinetic/Pharmacodynamic Analysis of Tedizolid Phosphate Compared to Linezolid for the Treatment of Infections Caused by Gram-Positive Bacteria
Previous Article in Journal
Antimicrobial Resistance Determinants in Genomes and Plasmids from Acinetobacter baumannii Clinical Isolates
Previous Article in Special Issue
“Repurposing” Disulfiram in the Treatment of Lyme Disease and Babesiosis: Retrospective Review of First 3 Years’ Experience in One Medical Practice
Perspective

Evidence-Based, Patient-Centered Treatment of Erythema Migrans in the United States

Partnership for Tick-Borne Diseases Education, P.O. Box 84, Wyoming, MN 55092, USA
Academic Editors: John Lambert and Brendan O. Kelly
Antibiotics 2021, 10(7), 754; https://doi.org/10.3390/antibiotics10070754
Received: 11 May 2021 / Revised: 18 June 2021 / Accepted: 18 June 2021 / Published: 22 June 2021
(This article belongs to the Special Issue The Evidence Base for Treatment of Tickborne Infections)
Lyme disease, often characterized as a readily treatable infection, can be a debilitating and expensive illness, especially when patients remain symptomatic following therapy for early disease. Identifying and promoting highly effective therapeutic interventions for US patients with erythema migrans (EM) rashes that return them to their pre-infection health status should be a priority. The recently released treatment recommendations by the Infectious Diseases Society of America/American Academy of Neurology/American College of Rheumatology (IDSA/AAN/ACR) for the treatment of US patients fall short of that goal. This paper reviews the US trial evidence regarding EM rashes, discusses the shortcomings of the IDSA/AAN/ACR recommendations in light of that evidence and offers evidence-based, patient-centered strategies for managing patients with erythema migrans lesions. View Full-Text
Keywords: erythema migrans; amoxicillin; cefuroxime; doxycycline; treatment; Lyme disease; antibiotic; patient-centered erythema migrans; amoxicillin; cefuroxime; doxycycline; treatment; Lyme disease; antibiotic; patient-centered
MDPI and ACS Style

Maloney, E.L. Evidence-Based, Patient-Centered Treatment of Erythema Migrans in the United States. Antibiotics 2021, 10, 754. https://doi.org/10.3390/antibiotics10070754

AMA Style

Maloney EL. Evidence-Based, Patient-Centered Treatment of Erythema Migrans in the United States. Antibiotics. 2021; 10(7):754. https://doi.org/10.3390/antibiotics10070754

Chicago/Turabian Style

Maloney, Elizabeth L. 2021. "Evidence-Based, Patient-Centered Treatment of Erythema Migrans in the United States" Antibiotics 10, no. 7: 754. https://doi.org/10.3390/antibiotics10070754

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop